Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: Applications of different configurations of novel glucagon peptide 1 with fatty acid modification or nonmodification in the treatment of T2D or the pancreas protection are provided. The dimer of the present disclosure is formed by two identical cysteine-containing GLP-1 monomers through a disulfide bond. The H-like GLP-1 homodimer (disulfide bond is inside chains) showed remarkable increase in hypoglycemic duration without reducing specific activity. The GLP-1 dimer provided has an in-vivo effective duration of up to 19 days, which significantly prolonged compared with that of the positive control drug Liraglutide with 3 days of effective duration, or thereby greatly promoting the technical advancement in long-acting GLP-1 drugs and facilitating their clinical applications and business. Meanwhile the U-like homodimer (disulfide bond is at the C-terminus) does not affect blood glucose, but can obviously protect pancreatic exocrine cells such as acini and ducts, and improve pancreas function.

Abstract: Optical coherence tomography (OCT) angiography (OCTA) data is generated by one or more machine learning systems to which OCT data is input. The OCTA data is capable of visualization in three dimensions (3D) and can be generated from a single OCT scan. Further, motion artifact can be removed or attenuated in the OCTA data by performing the OCT scans according to special scan patterns and/or capturing redundant data, and by the one or more machine learning systems.

Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: An ultrasonic data transmission method, apparatus and system, a terminal device and a medium are provided. The method is applied to a transmitting terminal which includes at least two ultrasonic signal transmitting arrays. The method includes: a single-frequency ultrasonic coding signal of to-be-transmitted information corresponding to each ultrasonic signal transmitting array is respectively determined, ultrasonic codes of to-be-transmitted information corresponding to different ultrasonic signal transmitting arrays being different; and corresponding at least two single-frequency ultrasonic code signals are transmitted through the at least two ultrasonic signal transmitting arrays to a receiving terminal in a focusing mode, frequency bands of transmitting frequencies of different ultrasonic signal transmitting arrays being different.

Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: A medical diagnostic apparatus includes a receiver circuit that receives three-dimensional volumetric data of a subject’s eye, and a processor configured to separate portions of the three-dimensional volumetric data into separate segments, perform processing differently on each of the separate segments, and combine the separately processed segments to produce an enhanced three-dimensional volumetric data set. The processor is further configured to generate at least one diagnostic metric from the enhanced three-dimensional volumetric data set, and the processor is further configured to evaluate a pathological condition based on the at least one diagnostic metric. Related methods and computer readable media are also disclosed.

Abstract: The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: A low coherence imaging method comprises acquiring image data of an object with an interferometric imaging system, where the image data is from a location of the object at first and second times; determining a first depth profile from the image data from the location at the first time and a second depth profile from the image data of the location at the second time; determining a change with respect to depth between the first and second depth profiles; and determining a property, or identifying a location, of at least one dynamic particle in the object based on the change between the first and second depth profiles. The method is able to identify, analyze, and/or visualize dynamic particles with features comparable to at least fluorescein angiography, indocyanine green angiography, confocal scanning laser fluorescein angiography, confocal scanning laser indocyanine green angiography, and fluorescence microscopy images, without the use of a dye.

Abstract: A frequency combination corresponding to target data to be transmitted is determined. The frequency combination includes at least two different frequencies. Ultrasonic waves of frequencies in the frequency combination are sent within a predetermined duration.

Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract: A medical diagnostic apparatus includes a receiver circuit that receives three-dimensional data of a subject's eye, and a processor configured to separate portions of the three-dimensional data into separate segments, perform processing differently on each of the separate segments, and combine the separately processed segments to produce a segmented three-dimensional data set. The processor is further configured to generate at least one diagnostic metric from the segmented three-dimensional data set, and the processor is further configured to evaluate a pathological condition based on the at least one diagnostic metric. Related methods and computer readable media are also disclosed.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: An interferometric method of identifying the thickness of an object that is too thin to be resolved by a Fourier transform of the interference signal includes applying a harmonic frequency modulation to an envelope of the interference signal. Where the object is a tear film, this method may be utilized to determine a thickness of the lipid layer of the tear film.